Zyflo Related Published Studies
Well-designed clinical trials related to Zyflo (Zileuton)
Randomized trial of zileuton for treatment of COPD exacerbations requiring hospitalization. [2011.02]
Randomized trial of zileuton for treatment of COPD exacerbations requiring
hospitalization. [2011]
Efficacy of zileuton controlled-release tablets administered twice daily in the treatment of moderate persistent asthma: a 3-month randomized controlled study. [2007.08]
Clinical pattern of zileuton-associated liver injury: results of a 12-month study in patients with chronic asthma. [2007]
Effects of 5-lipoxygenase inhibitor zileuton on airway responses to inhaled swine house dust in healthy subjects. [2006.02]
Well-designed clinical trials possibly related to Zyflo (Zileuton)
Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203. [2008.02.20]
The effects of a 5-lipoxygenase inhibitor on acute mountain sickness and urinary leukotriene e4 after ascent to high altitude. [2005.02]
Other research related to Zyflo (Zileuton)
Role of add-on zileuton on total exhaled, large airway, and small airway/alveolar nitric oxide in moderate-severe persistent adult asthmatics on fluticasone 250 microg/Salmeterol 50 microg. [2009.12]
5-lipoxygenase inhibitor zileuton attenuates ischemic brain damage: involvement of matrix metalloproteinase 9. [2009.10]
Role of add-on zileuton on total exhaled, large airway, and small airway/alveolar nitric oxide in moderate-severe persistent adult asthmatics on fluticasone 250mug/Salmeterol 50mug. [2009.05.23]
Zileuton added to low-dose inhaled beclomethasone for the treatment of moderate to severe persistent asthma. [2007.06]
Anti-inflammatory activity of a potent, selective leukotriene A4 hydrolase inhibitor in comparison with the 5-lipoxygenase inhibitor zileuton. [2007.06]
The safety and efficacy of zileuton controlled-release tablets as adjunctive therapy to usual care in the treatment of moderate persistent asthma: a 6-month randomized controlled study. [2007.05]
Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease. [2007.04]
Zileuton added to low-dose inhaled beclomethasone for the treatment of moderate to severe persistent asthma. [2007.03.12]
Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventive effects of zileuton and celecoxib. [2005.03.01]
Zileuton, an oral 5-lipoxygenase inhibitor, directly reduces sebum production. [2005]
Other possibly related research studies
Leukotriene inhibitors in the treatment of allergy and asthma. [2007.01.01]
Effect of leukotriene modifier drugs on the safety of oral aspirin challenges. [2006.11]
Treatment of asthma with antileukotrienes: first line or last resort therapy? [2006.03.08]
Effect of licofelone against mechanical hyperalgesia and cold allodynia in the rat model of incisional pain. [2005.05]
Effects of selective COX-2 and 5-LOX inhibition on prostaglandin and leukotriene synthesis in ductal pancreatic cancer in Syrian hamster. [2005.08]
Pharmacological inhibition of leukotrienes in an animal model of bleomycin-induced acute lung injury. [2006.11.21]
Gateways to clinical trials. [2006.09]
Gateways to clinical trials. [2006.07]
The role of leukotrienes in the pathophysiology of inflammatory disorders: is there a case for revisiting leukotrienes as therapeutic targets? [2006.03]
In vitro 12(S)-HETE and leukotriene metabolism inhibitory activity of sesquiterpenes of Warburgia ugandensis. [2006.06]
Is there a role for antileukotrienes in urticaria? [2006.05]
Gateways to clinical trials. [2006.01]
Gateways to clinical trials. [2005.09]
Correlation of in vitro chemopreventive efficacy data from the human epidermal cell assay with animal efficacy data and clinical trial plasma levels. [2005.06.01]
Asthma controller therapy during pregnancy. [2005.02]
Licofelone--a novel analgesic and anti-inflammatory agent. [2007]
Effects of leukotriene inhibition on pulmonary morphology in rat pup lungs exposed to hyperoxia. [2007.04]
Effects of novel 5-lipoxygenase inhibitors on the incidence of pulmonary adenomas in the A/J murine model when administered via nose-only inhalation. [2007.05]
Treatment heterogeneity in asthma: genetics of response to leukotriene modifiers. [2007]
Cysteinyl-leukotrienes and their receptors in asthma and other inflammatory diseases: critical update and emerging trends. [2007.07]
Pharmacological intervention to the inflammatory response from decompression sickness in rats. [2008.02]
Role of long-acting beta2-adrenergic agonists in asthma management based on updated asthma guidelines. [2008.01]
Effect of dexamethasone associated with serum therapy on treatment of Bothrops jararaca venom-induced paw edema in mice. [2007.10]
Gateways to clinical trials. [2007.12]
Overexpression of 5-lipoxygenase in colon polyps and cancer and the effect of 5-LOX inhibitors in vitro and in a murine model. [2008.10.15]
Gateways to clinical trials. [2008.05]
Concurrent blockade of platelet-activating factor and histamine prevents life-threatening peanut-induced anaphylactic reactions. [2009.08]
Topical chemoprevention of skin cancer in mice, using combined inhibitors of 5-lipoxygenase and cyclo-oxygenase-2. [2009.08]
5-lipoxygenase pharmacogenetics in asthma: overlap with Cys-leukotriene receptor antagonist loci. [2009.03]
Leukotriene pathways and in vitro adenotonsillar cell proliferation in children with obstructive sleep apnea. [2009.05]
Blockade of cytosolic phospholipase A2 alpha prevents experimental autoimmune encephalomyelitis and diminishes development of Th1 and Th17 responses. [2008.11.15]
Synthesis and pharmacological evaluation of 2-substituted benzo[b]thiophenes as anti-inflammatory and analgesic agents. [2009.04]
Systemic therapies in managing sinonasal inflammation. [2010.06]
Antileukotriene drugs in the treatment of asthma. [2010.03]
Metabolomics in drug intolerance. [2009.11]
Simultaneous determination of ABT-888, a poly (ADP-ribose) polymerase inhibitor, and its metabolite in human plasma by liquid chromatography/tandem mass spectrometry. [2010.02.01]
Targeting Ca2+ release-activated Ca2+ channel channels and leukotriene receptors provides a novel combination strategy for treating nasal polyposis. [2009.11]
When surgery, antibiotics, and steroids fail to resolve chronic rhinosinusitis. [2009.11]
The Alox5 gene is a novel therapeutic target in cancer stem cells of chronic myeloid leukemia. [2009.11.01]
Induction of leukotriene B(4) and prostaglandin E(2) release from keratinocytes by protease-activated receptor-2-activating peptide in ICR mice. [2009.10]
CJ-13610, an orally active inhibitor of 5-lipoxygenase is efficacious in preclinical models of pain. [2009.09.01]
Association between leukotriene-modifying agents and suicide: what is the evidence? [2011.07.01]
5-Lipoxygenase metabolite 4-HDHA is a mediator of the antiangiogenic effect of omega-3 polyunsaturated fatty acids. [2011.02.09]
Pranlukast attenuates hydrogen peroxide-induced necrosis in endothelial cells by inhibiting oxygen reactive species-mediated collapse of mitochondrial membrane potential. [2011.04]
The employment of leukotriene antagonists in cutaneous diseases belonging to allergological field. [2010]
Pharmacological characterization of itch-associated response induced by repeated application of oxazolone in mice. [2010]
Hyperalgesic and edematogenic effects of peptides isolated from the venoms of honeybee (Apis mellifera) and neotropical social wasps (Polybia paulista and Protonectarina sylveirae). [2011.01]
CYFRA 21-1 as a prognostic and predictive marker in advanced non-small-cell lung
cancer in a prospective trial: CALGB 150304. [2012]
|
